中国STEMI住院患者指南I类推荐管理策略的实施表现
仅20.0%患者接受了全部9项推荐策略,再灌注治疗、出院β受体阻滞剂、出院ACEI/ARB及戒烟咨询执行率偏低,而双联抗血小板和他汀使用率较高,医院间差异显著且研究期间质量有所改善。
要点
- 仅20.0%STEMI患者接受全部9项指南I类推荐策略。
- 再灌注治疗率61.0%,直接PCI 90分钟内完成率66.8%。
- 出院β受体阻滞剂68.3%、ACEI/ARB 55.1%、戒烟咨询36.5%。
核心结论
- 中国STEMI住院患者指南I类推荐策略的实施质量未达指南要求,仅五分之一患者接受全部推荐治疗。
主要发现
- 总体20.0%患者接受了全部9项指南I类推荐策略。
- 医院间全或无评分(all-or-none score)范围为0至61.9%,各单项措施执行率也存在显著差异;研究期间护理质量改善,尤其是再灌注治疗、入院90分钟内直接PCI和戒烟咨询。
关键数值与推荐
- 9项管理策略来自中国和美国指南的I类推荐。
- 再灌注治疗率61.0%,直接PCI 90分钟内完成率66.8%,溶栓30分钟内完成率22.4%。
- 出院β受体阻滞剂68.3%,出院ACEI/ARB 55.1%,戒烟咨询36.5%。
- 24小时内双联抗血小板95.5%,出院双联抗血小板91.8%,出院他汀93.0%。
- 医院间全或无评分范围0至61.9%。
临床怎么用
- 应针对再灌注治疗、出院β受体阻滞剂、ACEI/ARB及戒烟咨询等低执行率环节加强质量改进。
- 医院间差异显著,需推动标准化诊疗流程以减少变异。
局限性
- 研究仅纳入三级医院,结果可能不适用于其他级别医院。
- 为注册登记研究,可能存在数据报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite advances in the treatment of ST-segment elevation myocardial infarction (STEMI), little is known about how this evolving knowledge is applied in current clinical practice in China. OBJECTIVE: To evaluate hospital performance and temporal trends in the management of STEMI. DESIGN, SETTING, AND PARTICIPANTS: This study used data from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project, a nationwide quality improvement registry, in collaboration with the American Heart Association and the Chinese Society of Cardiology. Participants included patients with STEMI admitted to 143 tertiary hospitals across China from November 2014 to July 2019, and data were analyzed from November 2020 to December 2021. MAIN OUTCOMES AND MEASURES: Levels, hospital-level variations, and trends for utilization rates of the 9 management strategies with Class I recommendations in Chinese and US guidelines. RESULTS: A total of 57 560 hospitalizations with STEMI were included. Overall, 20.0% of patients received all the care according to the 9 guideline-recommended strategies. The performance rate of quality measures was low for reperfusion therapy (61.0%, 35 115/57 560 patients), β-blocker at discharge (68.3%, 37 750/55 285 patients), angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at discharge (55.1%, 2524/4578 patients), and smoking cessation counseling (36.5%, 9586/26 265 patients) among those who were eligible. Of 25 563 patients who underwent primary percutaneous coronary intervention (PCI), 66.8% underwent this procedure within 90 minutes of hospital arrival. Of 1128 patients who underwent fibrinolysis therapy, 253 (22.4%) underwent this treatment within 30 minutes of hospital arrival. Measures with high performance rates included receipt of dual antiplatelet therapy within 24 hours (95.5%, 54 263/56 848 patients) and at discharge (91.8%, 51 452/56 019 patients) and receipt of statin at discharge (93.0%, 52 214/56 141 patients) for those eligible. There was significant variation between hospitals in all-or-none score (ranging from 0 to 61.9%) and performance of individual measures. The quality of care improved during the study period, especially for reperfusion therapy, primary PCI within the first 90 minutes of hospital arrival, and smoking cessation counseling. CONCLUSIONS AND RELEVANCE: The quality of care for patients hospitalized with STEMI does not meet guideline-recommended strategies in China, with only 1 in 5 patients receiving all the care according to the 9 guideline-recommended strategies. Large disparities in the quality of care exist across hospitals.
引用
- Hao Y, Zhao D, Liu J, et al. Performance of Management Strategies With Class I Recommendations Among Patients Hospitalized With ST-Segment Elevation Myocardial Infarction in China. JAMA Cardiol. 2022. PMID: 35293976. doi:10.1001/jamacardio.2022.0117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。